International Isotopes Inc Announces Completion of Sale of Radiopharmaceutical Manufacturing Facility to NeoRx

Apr 20, 2001, 01:00 ET from International Isotopes Inc

    DENTON, Texas, April 20 /PRNewswire Interactive News Release/ --
 International Isotopes Inc (I3) announces that the transaction for the sale of
 its assets at its Jim Christal Road facility to NeoRx Corporation has been
 completed as of today.
     Dr. David M. Camp, Chairman and CEO of International Isotopes stated that
 agreements have been reached with virtually all of the unsecured creditors,
 removing the last substantial barriers to the completion of this transaction.
 Dr. Camp was quoted as saying, "All of the proceeds of this transaction and
 the transactions for the brachytherapy seed assets and the LINAC are directed
 at unsecured and secured creditors.  When the last of these transactions are
 completed, we expect that I3 will be relieved of most or all of the debt we
 owe, leaving the business with a viable future."
     Additionally, I3 announced that the closing of the sale of its
 brachytherapy seed business to Imagyn Medical Technologies, Inc., which had
 been expected to occur simultaneously with the NeoRx closing, is now expected
 to be completed by the end of April.
 
     Web site at: www.internationalisotopes.com
 
     International Isotopes Safe Harbor Statement
     Statements in the press release may constitute forward-looking statements
 and are subject to numerous risks and uncertainties, including the ability to
 meet time schedules, and other risks detailed from time to time in the
 Company's filings with the Securities and Exchange Commission.  The Company
 disclaims any obligation to update statements in this press release.
 
      For More Information, Contact:
      David Camp, President and CEO
      Paul Landers, Chief Financial Officer
      (940) 323-9672
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X28947235
 
 

SOURCE International Isotopes Inc
    DENTON, Texas, April 20 /PRNewswire Interactive News Release/ --
 International Isotopes Inc (I3) announces that the transaction for the sale of
 its assets at its Jim Christal Road facility to NeoRx Corporation has been
 completed as of today.
     Dr. David M. Camp, Chairman and CEO of International Isotopes stated that
 agreements have been reached with virtually all of the unsecured creditors,
 removing the last substantial barriers to the completion of this transaction.
 Dr. Camp was quoted as saying, "All of the proceeds of this transaction and
 the transactions for the brachytherapy seed assets and the LINAC are directed
 at unsecured and secured creditors.  When the last of these transactions are
 completed, we expect that I3 will be relieved of most or all of the debt we
 owe, leaving the business with a viable future."
     Additionally, I3 announced that the closing of the sale of its
 brachytherapy seed business to Imagyn Medical Technologies, Inc., which had
 been expected to occur simultaneously with the NeoRx closing, is now expected
 to be completed by the end of April.
 
     Web site at: www.internationalisotopes.com
 
     International Isotopes Safe Harbor Statement
     Statements in the press release may constitute forward-looking statements
 and are subject to numerous risks and uncertainties, including the ability to
 meet time schedules, and other risks detailed from time to time in the
 Company's filings with the Securities and Exchange Commission.  The Company
 disclaims any obligation to update statements in this press release.
 
      For More Information, Contact:
      David Camp, President and CEO
      Paul Landers, Chief Financial Officer
      (940) 323-9672
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X28947235
 
 SOURCE  International Isotopes Inc